Anubhav Sahu Moneycontrol Research -Diversified pharma major with a strong focus on complex generics -Plans to launch 56 complex products in the next five years in US market -Q4 sales helped by domestic market, US has improved sequentially -Key factors to watch: three site inspections and traction/approvals for new drugs -Business restructuring to help in post-tax return ratios Lupin (CMP: Rs 869 Market cap: Rs 39,407 crore) is known for its foray into complex generics. It was seen as an emerging Indian pharma MNC and a...
Moneycontrol Pro Panorama | Catch-22 for markets
May 17, 2022 / 03:21 PM IST
In today’s edition of Moneycontrol Pro Panorama: A quality bet, PPL’s tryst with market, what Adani buy means, Guruspeak and more
Read NowMoneycontrol Pro Weekender | Losing faith
May 7, 2022 / 10:05 AM IST
Central banks have a trust problem with financial markets over their ability to steer economies towards a soft landing
Read NowTo read the full story, Subscribe to Moneycontrol PRO
Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience
Already a member? Sign in
Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to
Ad free experience
Experience a non-intrusive navigation and faster response in the ad free mode
Sharpest Opinions
Access to 230+ exclusive stories per month from our editorial and Experts
+
Have a Global edge with access to content from world renowned experts and journalist
Actionable Insights
Access to 40+ weekly investment ideas including 4 daily technical calls
Virtual Events
Exclusive access to live webinars from market experts on trading and investment strategies
Newsletters
Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.
Get upto 50% discount on limited period offers